相关实验视频
Updated: May 25, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.5K
口服功能蛋白Z:通过抑制血栓激素缓解血栓形成,以预防心血管疾病
Chen Xu1, Hanhan Liu1, Mingyang Sun1
1College of Food Science & Nutritional Engineering, China Agricultural University, Beijing, China.
Colloids and surfaces. B, Biointerfaces
|February 25, 2025
概括
麦芽衍生蛋白Z (PZ) 显示出作为口服抗血栓食品丰富剂的潜力. 这种蛋白质通过向血栓来有效抑制血栓形成,这表明它是一种有前途的新方法来管理血栓性疾病.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 食品科学 食品科学 食品科学
背景情况:
- 血栓激素是血栓形成的关键酶,也是抗血栓治疗的目标.
- 开发新的口服抗血栓剂对于管理血栓性疾病至关重要.
研究的目的:
- 调查来自麦芽的血清蛋白酶抑制剂蛋白Z (PZ) 作为一种口服食品丰富剂,用于抑制血栓形成.
- 评估PZ的胃肠道稳定性,抗血栓机制和疗效.
主要方法:
- 在体外模拟胃肠道消化以评估PZ稳定性.
- 在体内实验评估PZ的胃肠道过境.
- 在体外抗血素活性测定中使用了两种血素基质.
- 药理动力学分析以确定PZ半衰期.
- 使用小鼠尾巴血栓形成模型进行体内抗血栓疗效评估.
主要成果:
- 在模拟的胃肠道消化和有效的胃肠道过境过程中,PZ表现出稳定性.
- PZ抑制了血栓激素活性,可能是通过向其活性部位或外位素1.
- PZ表现出有利的药理动力学特征,其半衰期为10.76±0.45分钟.
- 在小鼠中,PZ显著降低了血栓形成,与对照组相比,黑尾的发病率降低了51.23%.
结论:
- PZ是一种稳定且可口服生物利用的血清蛋白酶抑制剂,具有显著的抗血栓活性.
- PZ的抗血栓机制涉及在凝血通路内抑制血栓.
- PZ显示了作为治疗血栓性疾病的口服抗血栓性食物丰富剂的发展潜力.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
592
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
592
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455
Clot Retraction and Fibrinolysis
3.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142

